Screening for hepatitis B in chemotherapy patients: Survey of current oncology practices

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 2, 2010, Pages 240-246

  Tran, T T ^a   Rakoski, M O ^a   Martin, P ^b   Poordad, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ARTICLE; BIOCHEMISTRY; CHEMOTHERAPY; CLINICAL PRACTICE; DEMOGRAPHY; FISHER EXACT TEST; HEALTH SURVEY; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; NONHUMAN; ONCOLOGY; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; SCREENING; STATISTICAL ANALYSIS;

DNA, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK FACTORS; VIRUS ACTIVATION;

EID: 72949124159     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04158.x     Document Type: Article

References (41)

1. Yeo W, Chan PK, Zhon S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000 62 : 299 307.
2. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991 100 : 182 188.
3. Vassiliadis T, Garipidou V, Tziomalos K, et al. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy - a prospective case series. Am J Hematol 2005 80 : 197 203.
4. Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis carriers with hematologic malignancies: survey in Japan, 1987-1991. Cancer 1996 78 : 2210 2215.
5. Lim LL, Wai CT, Lee YM, et al. Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients. Aliment Pharmacol Ther 2002 16 : 1939 1944.
6. Hui CK, Cheung WW, Zhang H, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006 131 : 59 68.
7. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive therapy for hepatitis undergoing chemotherapy. Gastoenterology 2003 125 : 1742 1749.
8. Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkins lymphoma. Blood 1996 87 : 1202.
9. Ohtsu T, Sai T, Oka M, et al. Activation of hepatitis B virus infection by chemotherapy containing glucocorticoid in hepatitis B virus carriers with hematologic malignancies. Jpn J Clin Oncol 1991 21 : 360 365.
10. Skrabs C, Muller C, Agis H, et al. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia 2002 18 : 1884 1886.
11. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001 344 : 68 9.
12. Ng HJ, Lim LC. Fulminant hepatitis B reactivation with concomitant listeriosis after fludarabine and rituximab therapy: a case report. Ann Hematol 2001 80 : 549 552.
13. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004 90 : 1306 1311. (Pubitemid 38586252)
14. Yeo W, Johnson PJ. Diagnosis, prevention, and management of hepatitis B virus during anticancer therapy. Hepatology 2006 43 : 209 220.
15. Dai MS, Lu JJ, Chen YC, et al. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001 92 : 2927 2932.
16. Nordbo A, Skaug K, Holter E, et al. Reactivation of hepatitis B virus infection in an anti-HBc and anti-HBs positive patient after allogeneic bone marrow transplantation. Eur J Haematol 2000 65 : 86 7.
17. Lau GK, Ming-liang H, Fong DYT, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002 36 : 702 709.
18. Li Y, He Y, Jiang W, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006 106 : 1320 1325.
19. Kohrt HE, Ouyang DL, Keefe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharm Ther 2006 24 : 1003 1016.
20. Loomba R, Rowley A, Wesley R, et al. Systematic Review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Int Med 2008 148 : 519 528.
21. Yeo W, Steinberg JL, Tam JS, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999 59 : 263 269.
22. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 1989 73 : 911 917.
23. Thung SN, Gerber MA, Klion F, et al. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 1985 145 : 1313 1314.
24. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004 24 : 540 546.
25. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975 68 : 105 112.
26. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 : 215 229.
27. Yeo W, Chan PK, Chan HL, et al. Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 2001 65 : 473 477.
28. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009 50 : 227 242.
29. Midikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivatin after cytoxic chemotherapy: the disease and its prevention. Clin Gastroenterol and Hepatol 2006 4 : 1076 1081.
30. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Hematol 2007 136 : 699 712.
31. Keeffe EB, Dieterich DT, Han SB, et al. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 Update. Clin Gastroenterol and Hepatol 2008 6 : 1315 1341.
32. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 : 507 539.
33. Douglas DD, Rakela J, Wright TL, et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997 3 : 105 111.
34. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (+), HBIgM (-) organ donors. Transplantation 1995 59 : 230 234.
35. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haemiatol 2001 67 : 45 50.
36. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004 88 : 209 215.
37. Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004 11 : 55 9.
38. Nagamatsu H, Kumashiro R, Itano S, et al. Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 2003 26 : 293 301.
39. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005 54 : 1597 1603.
40. Lai CL, Ching CK, Tung AKM, et al. Lamividine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997 25 : 241 244.
41. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepaitits B. Gastroenterology 2000 119 : 172 180.